Pfizer Inc. (ETR:PFE)
Germany
· Delayed Price · Currency is EUR | Market Cap | 111.71B |
| Revenue (ttm) | 61.46B |
| Net Income (ttm) | 7.76B |
| Shares Out | n/a |
| EPS (ttm) | 1.36 |
| PE Ratio | 14.40 |
| Forward PE | n/a |
| Dividend | 1.58 (8.07%) |
| Ex-Dividend Date | Jan 24, 2025 |
| Volume | 78,699 |
| Average Volume | 122,464 |
| Open | 20.02 |
| Previous Close | 19.57 |
| Day's Range | 19.67 - 20.27 |
| 52-Week Range | 18.57 - 29.50 |
| Beta | 0.60 |
| RSI | 29.52 |
| Earnings Date | Apr 29, 2025 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial numbers in USD Financial StatementsNews
Pfizer declares $0.43 dividend
Pfizer Declares Second-Quarter 2025 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2025 dividend on the company’s common stock, payable June 13, 2025, to holders of the Common Stock o...
Pfizer Declares Second-Quarter 2025 Dividend
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2025 dividend on the company's common stock, payable June 13, 2025, to ho...
Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting
Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 ...
Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO®) Annual M...
Pfizer Earnings Preview: Pharma May Plumb New Depths After Obesity Drug Debacle
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (April 2025)
Shares of Pfizer (NYSE: PFE) have been battered over the past month, falling by -16.44%, outpacing the market’s loss of -9.44% over the same period. Since hitting its one-year high on July 30, 2024, P...
Upcoming Pfizer Earnings Call Might Be Focused On Tariffs, Policy Risks And Obesity Pipeline
Pfizer Inc (NYSE: PFE) is scheduled to release its first quarter 2025 earnings on 29 April . Analysts forecast adjusted earnings of 70 cents per share with sales of $14.26 billion . BofA updated its ...
LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
Pfizer: Is The Dividend Yield Worth The Effort
Pfizer (PFE) Faces Activist Pressure from Starboard Value
Pfizer (PFE) Faces Activist Pressure from Starboard Value
Pfizer Abandons Its Leading Weight Loss Candidate. Should You Sell the Stock?
Pfizer: Risks Priced In, Buy The Exceptional Valuation And Yield
Pfizer gets ACIP backing as it votes to expand RSV vaccine recommendation
ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO to Include Adults Aged 50 to 59 at Increased Risk of Disease
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the ...
ACIP Votes to Expand Recommendation for Pfizer's RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand ...
Pfizer: Tasty 7% Yield
Pfizer (PFE) Stock Moves Despite Drug Development Halt
Pfizer (PFE) Stock Moves Despite Drug Development Halt
Why Pfizer Stock Topped the Market on Tuesday
Trump signs healthcare executive order that includes a win for pharma companies
U.S. President Donald Trump directed his health department on Tuesday to work with Congress on revamping a law that allows Medicare to negotiate prescription drug prices, seeking to introduce a change...
Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes
European pharma companies issue demands to stay in EU ahead of expected US tariffs
Nearly three dozen global pharmaceutical companies, in a letter to the head of the European Commission, demanded help to maintain operations in the EU despite threatened U.S. tariffs on imports, inclu...
Tariffs on generic drugs will cause companies to stop making them: Former FDA Commissioner Gottlieb
Dr. Scott Gottlieb, former FDA Commissioner, joins 'Squawk Box' to discuss current pharmaceutical imports under investigation, moving production for branded and generic drugs elsewhere, and much more.
The Tariff Game Just Changed: 7 Blue-Chip Bargains To Buy Now
Unprecedented Opportunities: Recent market panic has created deep discounts among world-class blue-chip companies trading at 52-week lows, offering up to 100% potential returns and secure yields appro...
Pfizer stops working on potential pill to treat obesity after study participant has liver injury
Pfizer had intended to move the drug into late-stage testing, but called it quits after a patient in a clinical trial experienced a potentially drug-related liver injury.